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Purpose: Urinary biomarker tests for diagnosing prostate cancer have gained
considerable interest. Urine is a complex mixture that can be subfractionated.
We evaluated 2 urinary fractions that contain nucleic acids, ie cell pellets and
exosomes. The influence of digital rectal examination before urine collection was
also studied and the prostate cancer specific biomarkers PCA3 and TMPRSS2-
ERG were assayed.
Materials and Methods: Urine samples were prospectively obtained before and
after digital rectal examination from 30 men scheduled for prostate biopsy. Cell
pellet and exosomes were isolated and used for biomarker analysis. Analytical
and diagnostic performance was tested using the Student t-test and ROC curves.
Results: Unlike the exosome fraction, urinary sediment gene expression analysis
was compromised by amorphous precipitation in 10% of all specimens. Digital
rectal examination resulted in increased mRNA levels in each fraction. This was
particularly relevant for the exosomal fraction since after digital rectal exami-
nation the number of samples decreased in which cancer specific markers were
below the analytical detection limit. Biomarker diagnostic performance was
comparable to that in large clinical studies. In exosomes the biomarkers had to
be normalized for prostate specific antigen mRNA while cell pellet absolute PCA3
levels had diagnostic value.
Conclusions: Exosomes have characteristics that enable them to serve as
a stable substrate for biomarker analysis. Thus, digital rectal examination
enhances the analytical performance of biomarker analysis in exosomes and
cell pellets. The diagnostic performance of biomarkers in exosomes differs from
that of cell pellets. Clinical usefulness must be prospectively assessed in larger
clinical cohorts.
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PROSTATE cancer is the most common
malignancy in males in developed
countries and the third leading cause
of cancer related death in this popu-
lation.1 The gold standard of PCa
diagnosis is based on histopathological
examination of prostate biopsies. The
indication for prostate biopsies pri-
marily relies on serum PSA and/or
suspicious DRE. The introduction
of serum PSA testing led to a consid-
erable increase in the number of
Abbreviations
and Acronyms
BDL ¼ below analytical detection
limit
DNase ¼ deoxyribonuclease
DRE ¼ digital rectal examination
PCa ¼ prostate cancer
PCA3 ¼ PCa antigen 3
PCR ¼ polymerase chain reaction
PSA ¼ prostate specific antigen
TMPRSS2 ¼ transmembrane
protease serine 2
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prostate biopsies, which in turn led to an increase
in the PCa incidence. Although serum PSA has low
specificity for detecting PCa, it is currently the
only biomarker used in clinical practice for PCa
diagnosis. However, it does not differentiate between
indolent and clinically significant PCa. Therefore,
better diagnostic and monitoring tools are ur-
gently needed.
A new biomarker should ideally meet certain
criteria. It should be a noninvasive test that is
produced by tumor tissue only and has the ability
to detect PCa at an early stage. Thus, it should
differentiate aggressive from indolent tumors with
high specificity and sensitivity.
To date several urinary biomarkers for PCa
have been investigated. In 1999 Bussemakers et al
noted that the prostate specific noncoding RNA
DD3, better known as PCA3, is highly over expressed
in prostate tumor tissue.2 Further research recently
led to Food and Drug Administration approval
of the commercially available PCA3 urine test,
calculated as PCA3 mRNA/PSA mRNA  1,000, as
a decision making aid for repeat biopsy. Another
biomarker strongly associated with malignant pros-
tate epithelial cells is the TMPRSS2-ERG gene
fusion transcript.3 This androgen regulated gene
fusion is found in almost 50% of patients with PCa
and it is absent in nonPCa specimens.4 Each
biomarker can be measured noninvasively in uri-
nary samples.
Urinary samples can be a noninvasive substrate
for biomarker analysis using various components of
urine. In most previous studies biomarkers were
analyzed in whole urine or urinary sediments.
Recent findings revealed that small tissue derived
vesicles called exosomes are a component of urine
and contain a wide variety of proteins and RNAs
that represent the tissue of origin.5,6 However, few
groups have examined the role of these exosomes as
a novel substrate for PCa biomarkers.79
Biomarker expression in urinary samples is ex-
pected to be higher after performing DRE, consid-
ering that prostate manipulation mobilizes cancer
cells, if present, via the prostatic ductal system
into the urethra. Subsequently, first catch urine
contains the highest concentration of prostate
secretions, including cells. This hypothesis was
investigated in previous series.10,11 In a pilot study
Nilsson et al noted that mild prostate manipulation
increased exosomal secretion into the first catch
urinary fraction.8
We further investigated urinary exosomes as a
substrate for PCa biomarkers by assaying PCA3
and TMPRSS2-ERG in cell pellets and exosomes
before and after DRE. PSA mRNA levels were deter-
mined for normalization as a prostate reference
gene. The diagnostic value of PCA3 in exosomes
and cell pellets for biopsy outcome prediction was
also evaluated.
MATERIALS AND METHODS
Data Collection
Urinary samples were prospectively taken from 30 pa-
tients at the outpatient clinic of 2 university hospitals in
The Netherlands in an almost equal ratio. Approval was
obtained from the institutional review boards in accor-
dance with all medical ethical requirements. Patients
were scheduled for prostate biopsies based on PSA (3 ng/
ml or greater) and/or abnormal DRE. After obtaining
written informed consent first catch urine collection was
done without DRE. Standardized DRE was then per-
formed with firm pressure to the prostate from base to
apex and from the lateral to the medial side.12 Directly
after DRE a second first catch urine sample was collected
and transrectal ultrasound guided prostate biopsies were
obtained according to the local protocol (8 to 16 cores).
Pathology results and all other clinical data were collected
prospectively.
Cell Pellet and Exosome Isolation
Coded 50 ml transfer tubes containing 4 ml 0.5 M ethyl-
enediaminetetraacetic acid were used for urine collection.
After collection samples were immediately cooled and
processed within 48 hours to maintain optimal sample
quality. Analysis was done at a central laboratory.
Cell pellet and exosome isolation were performed
according to a validated procedure.13 Cell pellets were
separated from supernatant at 1,800  gravity for
10 minutes at 4C, washed twice with ice-cold buffered
sodium chloride solution, snap frozen in liquid nitrogen
and stored at 70C. Cellular debris was removed from
supernatant containing exosomes by centrifuging at
3,200  gravity for 90 minutes at 4C, followed by filtration
using a 0.8 mm filter. The concentrate containing exo-
somes was obtained by filtration through a 100 kDa filter
using a Vivaspin centrifuge. The acquired exosome
content was washed twice with ice-cold buffered sodium
chloride solution, snap frozen in liquid nitrogen and
stored at 70C.
Real-Time PCR RNA Extraction and Gene
Expression Analysis
RNA was extracted from exosomes and cell pellets using
a modified TriPure Reagent protocol (catalogue No.
11667165001). GlycoBlue (15 mg/ml, catalogue No. AM
9515) served as the carrier to co-precipitate RNA. RNA
samples were treated with DNase for 10 minutes before
the amplification protocol using DNase I enzyme (cata-
logue No. 18068-015, Invitrogen).
Total RNA was used to generate amplified sense
strand cDNA using the Whole Transcriptome Analysis
Kit (catalogue No. 4411974, Ambion) according to the
manufacturer protocol. PSA, PCA3 and TMPRSS2-ERG
expression levels were analyzed by quantitative real-
time PCR, normalized to the amount of urine used and
expressed in copies per ml. The supplementary table
(http://jurology.com/) lists the designed primer pairs and
hydrolysis probe sequences used. Two ml of each cDNA
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sample were amplified in a 20 ml PCR reaction containing
10 mmol of each primer, 2 mmol hydrolysis probe and
1 Probes Master mix (Roche, Indianapolis, Indiana).
Control samples served as the referent. Amplification
conditions were 95C for 10 minutes followed by 50 cycles
at 95C for 10 seconds and 60C for 30 seconds with cooling
at 40C for 55 seconds using a LightCycler LC480.
LightCycler 480 SW 1.5 software was used to determine
crossing point values. Calibration curves with a wide
linear dynamic range (10 to 1,000,000 copies) were
generated using plasmid serial dilutions. We converted
sample crossing point values to concentrations by
extrapolation in the generated calibration curve.
The cutoff value for an adequate amount of prostate
content was set at 1,000 copies of PSA mRNA.14 Copy
numbers below this cutoff were assumed to contain an
insufficient amount of prostate specific transcripts and be
less accurate and reliable. Therefore, they were excluded
from further diagnostic analysis. To test the analytical
performance no exclusion was done based on the
mentioned criteria since the amount of prostate specific
transcripts measured could possibly have been influenced
by DRE.
Electron Microscopy
Exosome isolation for electron microscopy imaging was
done in 1 urine sample according to the mentioned
methods. For immunoelectron microscopy exosome iden-
tification we used the protocol described by L€asser et al.15
Figure 1 shows a urinary exosome.
Statistical Analysis
Data were analyzed using SPSS, version 18.0.2. To
test for differences in biomarker expression before vs
after DRE we used the paired sample t-test after log
transformation of data. ROC curve analysis and the AUC
were applied to calculate diagnostic accuracy.
RESULTS
Patient Characteristics
A total of 30 patients were included in study, from
whom a total of 60 urinary samples were collected.
For analysis we used a urinary sample obtained
before and after DRE from each patient. All men
subsequently underwent transrectal ultrasound
guided prostate biopsies. PCa was found in the
biopsy specimen in 14 patients (47%). Table 1 lists
patient characteristics.
The amount of urine collected before DRE was
similar to the amount collected after DRE (mean
36.8 and 39.2 ml, respectively, p ¼ 0.255). In
3 samples (10%) before DRE and 3 (10%) after
DRE no RNA was extracted from the cell pellet due
to precipitation of impurities (crystals). Three
samples (5%) did not fulfill the predetermined
cutoff values for a sufficient amount of prostate
specific transcripts, including 2 samples before and
1 after DRE. Another sample was lost in the RNA
extraction process. For urinary exosomes no pre-
cipitation occurred. However, 9 samples (30%)
before DRE and 6 (20%) after DRE did not fulfill
the predetermined cutoff values for a sufficient
amount of prostate specific transcripts. Therefore,
for PCA3 mRNA diagnostic evaluation 25 post-
DRE cell pellet samples and 24 post-DRE exo-
some samples remained. Table 2 lists the number
of samples with mRNA levels below BDL and
nonassessable samples. BDL was defined as PSA
less than 1,000 copies per ml and PCA3 less than
10 copies per ml.
Figure 1. Immunoelectron microscopy shows exosome isolated
from urine by ultrafiltration. Black dots attached to exosome
indicates exosomal surface marker CD63. Scale bar indicates
100 nm.
Table 1. Patient characteristics
Prostate Ca No Prostate Ca Overall
No. pts (%) 14 (46.7) 16 (53.3) 30
Mean age (range) 67 (58e75) 65 (55e75) 66 (55e75)
Mean ng/ml serum PSA (range) 9.11 (4.2e32.6) 9.85 (2.9e27.7) 9.51 (2.9e32.6)
No. Gleason score (%): e e
6 6 (42.9)
Greater than 6 8 (57.1)
Mean cc prostate vol (range) 49.7 (23e107) 66.1 (24e124) 58.5 (23e124)
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RNA Analysis
In total RNA from urinary sediments (cell pellets)
we noted prominent 18S and 28S peaks, represent-
ing rRNA. However, analysis of exosomal RNA
showed a small, pronounced RNA peak between
25 and 200 nucleotides, and little or no ribosomal
RNA. After treating the exosomal fraction with
ribonuclease and DNase the extra-exosomal RNA
and DNA were removed, resulting in exosome spe-
cific transcript preparations.
DRE and Biomarker Levels
Figure 2 shows the influence of DRE on biomarker
expression levels in cell pellets and exosomes iso-
lated from urinary samples. In the cell pellet frac-
tion after DRE an increase in PSA mRNA was noted
in 24 of 30 samples (80%), 22 of 30 (73.3%) showed
an increase in PCA3 mRNA and 5 of 6 (83.3%) were
Table 2. Nonassessable and BDL samples of 60 cell pellet and
exosome samples
No. PSA (%) No. PCA3 (%)
Before DRE After DRE Before DRE After DRE
Cell pellet:
Nonassessable 3 (10) 3 (10) 3 (10) 3 (10)
BDL 2 (6.7) 1 (3.3) 7 (23.3) 2 (6.7)
Exosome BDL* 9 (30) 6 (20) 17 (56.7) 5 (16)
*No exosomes were nonassessable.
Figure 2. PSA mRNA in cell pellet (A) and exosomes (B), PCA3 mRNA in cell pellet (C ) and exosomes (D), and TMPRSS2-ERG mRNA
in cell pellet (E ) and exosomes (F ) before and after DRE.
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positive for TMPRSS2-ERG. In exosomal isolation
samples an increase in PSA mRNA after DRE
was observed in 22 of 30 (73.3%), 23 of 30 (76.7%)
showed an increase in PCA3 and 4 of 4 (100%) were
positive for TMPRSS2-ERG. Mean biomarker levels
were significantly higher in cell pellets and exo-
somes after DRE (table 3).
Biomarker Diagnostic Performance
To assess the diagnostic performance of PCA3 we
calculated ROC curves for biopsy outcome predic-
tion (histologically confirmed PCa). As a continuous
variable, PCA3 mRNA copies showed an AUC of
0.67 (95% CI 0.45e0.89) in cell pellet samples before
DRE and 0.81 (95% CI 0.64e0.98) after DRE. No
reliable AUC could be calculated on exosome sam-
ples before DRE since in most samples mRNA levels
were below the detection limit and, thus, were ex-
cluded from this analysis (table 2). However, after
DRE when more samples could be included in
analysis, the AUC of absolute PCA3 mRNA was 0.52
(95% CI 0.28e0.76). When the quantitative PCA3
mRNA level was normalized to PSA mRNA (PCA3
mRNA/PSA mRNA  1,000), the AUC increased to
0.64 (95% CI 0.41e0.88) for exosomes. For cell pel-
lets the AUC changed to 0.67 (95% CI 0.46e0.89) in
samples obtained after DRE (fig. 3).
DISCUSSION
Although progress has been made, validating new
biomarkers in serum and urine remains a challenge.
Our data show that first catch urine after DRE re-
sults in a clear increase in biomarker levels and,
therefore, could contribute in PCa diagnosis. This
increase was observed in cell pellets and exosomes.
Table 3. Differences in biomarker expression in cell pellets and
exosomes before and after DRE after log transformation of
number of copies of mRNA/ml
Mean  SD Before DRE Mean  SD After DRE p Value
Pellets:
PSA 10.3  3.8 12.8  2.5 0.003
PCA3 6.5  4.6 9.5  3.4 0.001
TMPRSS2-ERG 0.3  1.5 1.4  2.6 0.032
Exosomes:
PSA 7.7  4.0 10.3  4.6 0.002
PCA3 2.9  3.6 7.4  4.2 0.000
TMPRSS2-ERG 0 1.0  2.6 0.047
Figure 3. PCA3 expression in cell pellets (A) and exosomes (B) by positive biopsy outcome (PCa þ) after DRE compared to negative
biopsy outcome (PCa ). Horizontal lines represent mean. ROC curves after DRE for PCA3 mRNA in cell pellets without
normalization for PSA mRNA and after normalization (AUC 0.81 and 0.67) (C ), and for exosomes (AUC 0.52 and 0.64, respectively) (D).
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Exosomes were first identified in human urine
in 2004 and recent findings revealed that these
small, tissue derived vesicles contain various RNAs,
representing their tissue origin.5,6,16 Exosomes are
the internal vesicles of multivesicular bodies, sug-
gesting that exosomal RNA would be protected
and better preserved than RNA in whole cells.
This difference between RNA from exosomes and
RNA derived from cells in urine was previously
described.13 It corresponds with our results showing
that microvesicles can resist ribonuclease and
DNase digestion, and still protect the nucleic acids
inside. In addition to this finding, the main differ-
ence between cell pellets and exosomes is that each
exosome sample was assessable for RNA extrac-
tion, ie none of the exosome samples contained
(in)organic precipitate while 3 cell pellet samples
(10%) could not be assessed due to precipitation. No
biomarker analysis can be performed in samples
that contain precipitation and the clinical conse-
quence of this would be resampling. The cell pellet
informative rate in this study is in accordance with
that in some earlier studies of PCA3 mRNA,
emphasizing the more stable nature of exosomes
over cell pellets.14,17
On the other hand, lower mRNA levels were
measured in exosomes and a significant number of
samples before DRE showed mRNA expression that
was BLD, including 17 samples in exosomes vs 7 in
cell pellets for PCA3 (table 2). However, this
improved significantly after DRE, that is 5 samples
in exosomes vs 2 in cell pellets. This supports the
value of DRE for determining biomarkers in urine.
Nevertheless, 16% to 20% of exosome samples did
not achieve the analytical detection limit. In clinical
practice these samples would be interpreted as
a negative test. Therefore, low analytical sensitivity
can lead to false-negative test results. This is
a detriment of exosomes and makes them not yet
suitable as a biomarker source for PCa diagnosis in
the clinical setting.
Despite our small sample size PCA3 analysis of
urinary sediments had diagnostic performance
similar to that in previous studies.12,14,18 When
exosomal RNA was analyzed, the levels of PCA3 and
TMPRSS2-ERG were significantly higher after
DRE. However, these biomarker levels in exosomes
seemed to have an insufficient correlation with the
prostate biopsy outcome. A hypothesis to explain
this finding may be that urinary microvesicles from
patients with PCa have a different content than
those from healthy donors and, therefore, they con-
tain less RNA, as previously described by Nilsson
et al.8 This would also explain the fact that more
exosome samples than cell pellet samples had
biomarker levels that were BDL. Notably, absolute
exosomal PCA3 copy numbers showed no diagnostic
value. However, when PCA3 levels were normalized
to PSA levels in the exosomes, the diagnostic value
improved. This is in agreement with the Progensa
PCA3 test in whole urine, which is also based on the
PCA3/PSA ratio. Since PSA mRNA expression is
relatively constant in normal prostate cells and PCa
cells, PSA mRNA expression is used for normaliza-
tion to noncancerous prostate cells.12,19
Our control group (negative biopsies) can be
considered a limitation since it was not represen-
tative of healthy men in the normal population.
Patients were selected for prostate biopsies based on
increased PSA and/or abnormal DRE. Thus, they
were at higher risk for a false-negative biopsy
outcome than healthy peers. Diagnostic data might
have been biased due to this limitation.
CONCLUSIONS
Comparative analysis of biomarkers in urinary
sediment (cell pellets) and exosomes showed that
exosomes seem to be a more robust source of bio-
markers, although exosomes have lower analytical
sensitivity. Furthermore, DRE resulted in higher
biomarker levels in first catch urine for cell pellets
and exosomes. However, the diagnostic performance
of PCA3 in exosomes appeared different from that
in cell pellets, ie PCA3 mRNA levels had to be
normalized to PSA mRNA to achieve diagnostic
improvement. Although we report that measuring
biomarkers in exosomes is feasible and results seem
promising, clinical usefulness and diagnostic value
must be prospectively explored in larger cohorts.
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